Mometasone - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (2)Enzymes (1)

Targets (2)Enzymes (1)Biointeractions (3)

Identification

Name

Mometasone

Accession Number

DB00764 (APRD00289)

Type

Small Molecule

Groups

Approved, Vet Approved

Description

Mometasone is a medium-potency synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. The anti-inflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

(+)-Mometasone

Mometason

Mometasona

Mométasone

Mometasonum

External IDs

LAS-41002 / LAS41002 / Sch 32088

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Mometasone furoate	04201GDN4R	83919-23-7	WOFMFGQZHJDGCX-ZULDAHANSA-N	Details
Mometasone furoate monohydrate	MTW0WEG809	141646-00-6	AQCCVUHZMIMSIB-HRVPQZBTSA-N	Details

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Asmanex	Inhalant	220 ug/1	Respiratory (inhalation)	Physicians Total Care, Inc.	2006-03-09	Not applicable	US
Asmanex	Inhalant	220 ug/1	Respiratory (inhalation)	Merck Sharp & Dohme Limited	2005-03-30	Not applicable	US
Asmanex	Inhalant	110 ug/1	Respiratory (inhalation)	Merck Sharp & Dohme Limited	2005-03-30	Not applicable	US
Asmanex HFA	Aerosol	100 ug/1	Respiratory (inhalation)	Merck Sharp & Dohme Limited	2014-04-25	Not applicable	US
Asmanex HFA	Aerosol	200 ug/1	Respiratory (inhalation)	Merck Sharp & Dohme Limited	2014-04-25	Not applicable	US
Asmanex Twisthaler	Powder	400 mcg	Respiratory (inhalation)	Merck Ltd.	2011-12-21	Not applicable	Canada
Asmanex Twisthaler	Powder	200 mcg	Respiratory (inhalation)	Merck Ltd.	2011-12-21	Not applicable	Canada
Asmanex Twisthaler	Powder	100 mcg	Respiratory (inhalation)	Merck Ltd.	2015-04-08	Not applicable	Canada
Elocom Cream	Cream	0.1 %	Topical	Merck Ltd.	1991-12-31	Not applicable	Canada
Elocom Lotion	Lotion	0.1 %	Topical	Merck Ltd.	1991-12-31	Not applicable	Canada
Elocom Ointment	Ointment	0.1 %	Topical	Merck Ltd.	1991-12-31	Not applicable	Canada
Elocon	Ointment	1 mg/g	Topical	Merck Sharp & Dohme Limited	1987-04-30	Not applicable	US
Elocon	Cream	1 mg/g	Topical	A S Medication Solutions	1987-05-06	2017-06-20	US
Elocon	Lotion	1 mg/mL	Topical	Merck Sharp & Dohme Limited	1989-03-30	Not applicable	US
Elocon	Cream	1 mg/g	Topical	Physicians Total Care, Inc.	1994-05-31	Not applicable	US
Elocon	Cream	1 mg/g	Topical	Merck Sharp & Dohme Limited	1987-05-06	Not applicable	US
Mometasone Furoate Monohydrate	Spray, metered	50 ug/1	Nasal	Sandoz	2016-03-25	Not applicable	US
Nasonex	Spray, metered	50 ug/1	Nasal	A S Medication Solutions	1997-10-01	2017-06-20	US
Nasonex	Spray, metered	50 mcg	Nasal	Merck Ltd.	1998-09-15	Not applicable	Canada
Nasonex	Spray, metered	50 ug/1	Nasal	Remedy Repack	2013-06-13	Not applicable	US
Nasonex	Spray, metered	50 ug/1	Nasal	Merck Sharp & Dohme Limited	1997-10-01	Not applicable	US
PMS-mometasone	Cream	.1 %	Topical	Pharmascience Inc	Not applicable	Not applicable	Canada
PMS-mometasone	Ointment	0.1 %	Topical	Pharmascience Inc	2003-11-25	Not applicable	Canada
PMS-mometasone	Ointment	0.1 %	Topical	Pharmascience Inc	2005-11-03	Not applicable	Canada
PMS-mometasone	Lotion	.1 %	Topical	Pharmascience Inc	Not applicable	Not applicable	Canada
Ratio-mometasone	Ointment	0.1 %	Topical	Teva	2003-11-04	Not applicable	Canada
Sandoz Mometasone	Spray, metered	50 mcg	Nasal	Sandoz Canada Incorporated	2016-07-27	Not applicable	Canada
Taro-mometasone Cream	Cream	0.1 %	Topical	Taro Pharmaceuticals, Inc.	2011-06-08	Not applicable	Canada
Taro-mometasone Lotion	Lotion	0.1 %	Topical	Taro Pharmaceuticals, Inc.	2009-12-01	Not applicable	Canada
Taro-mometasone Ointment	Ointment	0.1 %	Topical	Taro Pharmaceuticals, Inc.	2005-06-21	Not applicable	Canada

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-mometasone	Spray, metered	50 mcg	Nasal	Apotex Corporation	2013-03-25	Not applicable	Canada
Mometasone Furoate	Spray, metered	50 ug/1	Nasal	Apotex Corporation	2016-03-21	Not applicable	US
Mometasone Furoate	Cream	1 mg/g	Topical	Proficient Rx LP	2008-05-28	Not applicable	US
Mometasone Furoate	Solution	1 mg/mL	Topical	Physicians Total Care, Inc.	2006-03-30	Not applicable	US
Mometasone Furoate	Ointment	1 mg/g	Topical	A S Medication Solutions	2008-07-18	2017-06-20	US
Mometasone Furoate	Ointment	1 mg/g	Topical	Impax Generics	2003-11-14	2017-07-06	US
Mometasone Furoate	Solution	1 mg/mL	Topical	E. Fougera & CO., A division of Fougera Pharmaceuticals Inc.	2007-11-29	Not applicable	US
Mometasone Furoate	Cream	1 mg/g	Topical	E. Fougera & CO., A division of Fougera Pharmaceuticals Inc.	2005-04-08	Not applicable	US
Mometasone Furoate	Ointment	1 mg/g	Topical	Remedy Repack	2017-05-12	Not applicable	US
Mometasone Furoate	Cream	1 mg/g	Topical	Rebel Distributors	2006-08-23	Not applicable	US
Mometasone Furoate	Ointment	1 mg/g	Topical	Gw Pharmaceuticals Ltd.	2014-03-04	Not applicable	US
Mometasone Furoate	Ointment	1 mg/g	Topical	Harris Pharmaceutical, Inc.	2006-10-18	Not applicable	US
Mometasone Furoate	Cream	1 mg/g	Topical	Proficient Rx LP	2004-12-21	Not applicable	US
Mometasone Furoate	Solution	1 mg/mL	Topical	Gw Pharmaceuticals Ltd.	2014-03-04	Not applicable	US
Mometasone Furoate	Ointment	1 mg/g	Topical	Perrigo New York Inc.	2008-07-18	Not applicable	US
Mometasone Furoate	Cream	1 mg/g	Topical	Clinical Solutions Wholsesale	2005-11-28	2017-06-24	US
Mometasone Furoate	Ointment	1 mg/g	Topical	Glenmark Pharmaceuticals Inc.,Usa	2008-05-28	Not applicable	US
Mometasone Furoate	Spray, metered	50 ug/1	Nasal	Av Kare, Inc.	2017-06-08	Not applicable	US
Mometasone Furoate	Cream	1 mg/g	Topical	Taro Pharmaceuticals U.S.A., Inc.	2004-12-21	Not applicable	US
Mometasone Furoate	Ointment	1 mg/g	Topical	E. Fougera & CO., A division of Fougera Pharmaceuticals Inc.	2005-03-28	Not applicable	US
Mometasone Furoate	Spray, metered	50 ug/1	Nasal	Golden State Medical Supply	2016-03-29	Not applicable	US
Mometasone Furoate	Cream	1 mg/g	Topical	Harris Pharmaceutical, Inc.	2006-08-23	Not applicable	US
Mometasone Furoate	Cream	1 mg/g	Topical	Physicians Total Care, Inc.	2006-03-30	Not applicable	US
Mometasone Furoate	Cream	1 mg/g	Topical	Proficient Rx LP	2007-04-18	Not applicable	US
Mometasone Furoate	Cream	1 mg/g	Topical	Impax Generics	2007-04-18	2017-07-06	US
Mometasone Furoate	Ointment	1 mg/g	Topical	Remedy Repack	2017-01-25	Not applicable	US
Mometasone Furoate	Solution	1 mg/mL	Topical	Perrigo New York Inc.	2008-12-11	Not applicable	US
Mometasone Furoate	Ointment	1 mg/g	Topical	Rebel Distributors	2006-10-18	Not applicable	US
Mometasone Furoate	Cream	1 mg/g	Topical	Perrigo New York Inc.	2004-12-21	Not applicable	US
Mometasone Furoate	Ointment	1 mg/g	Topical	Dispensing Solutions, Inc.	2006-10-18	Not applicable	US
Mometasone Furoate	Ointment	1 mg/g	Topical	Remedy Repack	2013-06-17	2017-01-24	US
Mometasone Furoate	Cream	1 mg/g	Topical	A S Medication Solutions	2004-12-21	2017-06-20	US
Mometasone Furoate	Lotion	1 mg/mL	Topical	Glenmark Pharmaceuticals Inc.,Usa	2010-08-09	Not applicable	US
Mometasone Furoate	Cream	1 mg/g	Topical	Nu Care Pharmaceuticals,inc.	2008-05-28	Not applicable	US
Mometasone Furoate	Cream	1 mg/g	Topical	Stat Rx USA	2006-08-23	Not applicable	US
Mometasone Furoate	Cream	1 mg/g	Topical	Gw Pharmaceuticals Ltd.	2006-08-23	Not applicable	US
Mometasone Furoate	Solution	1 mg/mL	Topical	Harris Pharmaceutical, Inc.	2014-03-04	Not applicable	US
Mometasone Furoate	Ointment	1 mg/g	Topical	Physicians Total Care, Inc.	2010-12-22	Not applicable	US
Mometasone Furoate	Cream	1 mg/g	Topical	A S Medication Solutions	2008-05-28	2017-06-20	US
Mometasone Furoate	Lotion	1 mg/g	Topical	Impax Generics	2007-11-21	2017-07-06	US
Mometasone Furoate	Spray, metered	50 ug/1	Nasal	Amneal Pharmaceuticals	2017-04-04	Not applicable	US
Mometasone Furoate	Cream	1 mg/g	Topical	A S Medication Solutions	2006-08-23	2017-06-20	US
Mometasone Furoate	Solution	1 mg/mL	Topical	Taro Pharmaceuticals U.S.A., Inc.	2006-03-15	Not applicable	US
Mometasone Furoate	Ointment	1 mg/g	Topical	Taro Pharmaceuticals U.S.A., Inc.	2004-12-03	Not applicable	US
Mometasone Furoate	Cream	1 mg/g	Topical	Glenmark Pharmaceuticals Inc.,Usa	2008-05-28	Not applicable	US

Approved Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Mosaspray	Spray, metered	50 mcg	Nasal	Sandoz Canada Incorporated	Not applicable	Not applicable	Canada
Nasal Allergy and Congestion Relief	Spray, metered	50 mcg	Nasal	Apotex Corporation	Not applicable	Not applicable	Canada
Nasonex Allergy and Congestion	Spray, metered	50 mcg	Nasal	Merck Ltd.	Not applicable	Not applicable	Canada

Unapproved/Other Products

Not Available

International Brands

Name	Company
Ecural	Essex pharma
Elocom	Merck
Elomet	Schering-Plough
Eziwin	Intas
mometAid	Progreś Laboratories
Novasone	Schering-Plough

Brand mixtures

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Dulera	Formoterol Mometasone	Aerosol	Respiratory (inhalation)	Merck Sharp & Dohme Limited	2010-06-22	Not applicable	US
Zenhale	Formoterol Mometasone	Aerosol, metered	Respiratory (inhalation)	Merck Ltd.	2011-03-10	Not applicable	Canada

Categories

UNII

8HR4QJ6DW8

CAS number

105102-22-5

Weight

Average: 427.361
Monoisotopic: 426.136464798

Chemical Formula

C₂₂H₂₈Cl₂O₄

InChI Key

QLIIKPVHVRXHRI-CXSFZGCWSA-N

InChI

InChI=1S/C22H28Cl2O4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1

IUPAC Name

(1R,2S,10S,11S,13R,14R,15S,17S)-1-chloro-14-(2-chloroacetyl)-14,17-dihydroxy-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one

SMILES

[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[[email protected]](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C

Pharmacology

Indication

The inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis.

Structured Indications

Pharmacodynamics

Mometasone is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. When glucocorticoids are discontinued, asthma stability may persist for several days or longer. Mometasone has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone. The clinical significance of these findings is unknown.

Mechanism of action

Unbound corticosteroids cross cell membranes and bind with high affinity to specific cytoplasmic receptors. Inflammation is decreased by diminishing the release of leukocytic acid hydrolases, prevention of macrophage accumulation at inflamed sites, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A₂ inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Mometasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Glucocorticoid receptor	Protein	yes	agonist	Human	P04150	details
Progesterone receptor	Protein	unknown	agonist	Human	P06401	details

Absorption

Nasal spray is virtually undetectable in plasma

Volume of distribution

Not Available

Protein binding

98% to 99% (in a concentration range of 5 to 500 ng/mL).

Metabolism

Hepatic. Extensive metabolism to multiple metabolites. There are no major metabolites detectable in plasma. Upon in vitro incubation, one of the minor metabolites formed is 6ß-hydroxy-mometasone furoate. In human liver microsomes, the formation of the metabolite is regulated by cytochrome P-450 3A4.

Substrate	Enzymes	Product
Mometasone	Not Available	6-beta-hydroxy-mometasone furoate	Details

Route of elimination

Not Available

Half life

5.8 hours

Clearance

Not Available

Toxicity

The potential for acute toxic effects following overdose with the mometasone inhaler is low. However, habitual overuse of the product can cause symptoms of steroid overload, including menstrual irregularities, acne, obesity, and muscle weakness. Single oral doses up to 8000 µg have been studied on human volunteers with no adverse events reported.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
1,10-Phenanthroline	The risk or severity of adverse effects can be increased when Mometasone is combined with 1,10-Phenanthroline.	Experimental
Aceclofenac	The risk or severity of adverse effects can be increased when Aceclofenac is combined with Mometasone.	Approved
Acetylsalicylic acid	The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Mometasone.	Approved, Vet Approved
Adapalene	The risk or severity of adverse effects can be increased when Adapalene is combined with Mometasone.	Approved
Aldesleukin	Mometasone may decrease the antineoplastic activities of Aldesleukin.	Approved
Aluminum hydroxide	The bioavailability of Mometasone can be decreased when combined with Aluminum hydroxide.	Approved
Ambenonium	The risk or severity of adverse effects can be increased when Mometasone is combined with Ambenonium.	Approved
Aminosalicylic Acid	The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Mometasone.	Approved
Amiodarone	The serum concentration of Mometasone can be increased when it is combined with Amiodarone.	Approved, Investigational
Amodiaquine	The serum concentration of Amodiaquine can be increased when it is combined with Mometasone.	Approved
Amphotericin B	Mometasone may increase the hypokalemic activities of Amphotericin B.	Approved, Investigational
Andrographolide	The risk or severity of adverse effects can be increased when HMPL-004 is combined with Mometasone.	Investigational
Anisodamine	The risk or severity of adverse effects can be increased when Anisodamine is combined with Mometasone.	Investigational
Antipyrine	The risk or severity of adverse effects can be increased when Antipyrine is combined with Mometasone.	Approved
Apocynin	The risk or severity of adverse effects can be increased when Acetovanillone is combined with Mometasone.	Investigational
Apremilast	The risk or severity of adverse effects can be increased when Apremilast is combined with Mometasone.	Approved, Investigational
Aprepitant	The serum concentration of Mometasone can be increased when it is combined with Aprepitant.	Approved, Investigational
Atazanavir	The serum concentration of Mometasone can be increased when it is combined with Atazanavir.	Approved, Investigational
Atracurium besylate	Atracurium besylate may increase the adverse neuromuscular activities of Mometasone.	Approved
Azapropazone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Mometasone.	Withdrawn
Azelastine	The risk or severity of adverse effects can be increased when Azelastine is combined with Mometasone.	Approved
Balsalazide	The risk or severity of adverse effects can be increased when Balsalazide is combined with Mometasone.	Approved, Investigational
Bazedoxifene	The serum concentration of Mometasone can be increased when it is combined with Bazedoxifene.	Approved, Investigational
Bendroflumethiazide	Mometasone may increase the hypokalemic activities of Bendroflumethiazide.	Approved
Benoxaprofen	The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Mometasone.	Withdrawn
Benzoic Acid	The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Mometasone.	Approved
Betulinic Acid	The risk or severity of adverse effects can be increased when Betulinic Acid is combined with Mometasone.	Investigational
Bismuth Subcitrate	The bioavailability of Mometasone can be decreased when combined with Bismuth Subcitrate.	Approved
Boceprevir	The serum concentration of Mometasone can be increased when it is combined with Boceprevir.	Withdrawn
Bromfenac	The risk or severity of adverse effects can be increased when Bromfenac is combined with Mometasone.	Approved
Bucillamine	The risk or severity of adverse effects can be increased when Bucillamine is combined with Mometasone.	Investigational
Bumetanide	Mometasone may increase the hypokalemic activities of Bumetanide.	Approved
Calcitriol	The therapeutic efficacy of Calcitriol can be decreased when used in combination with Mometasone.	Approved, Nutraceutical
Calcium Carbonate	The bioavailability of Mometasone can be decreased when combined with Calcium carbonate.	Approved
Carbamazepine	The serum concentration of Mometasone can be decreased when it is combined with Carbamazepine.	Approved, Investigational
Carprofen	The risk or severity of adverse effects can be increased when Carprofen is combined with Mometasone.	Approved, Vet Approved, Withdrawn
Castanospermine	The risk or severity of adverse effects can be increased when Castanospermine is combined with Mometasone.	Experimental
Celecoxib	The risk or severity of adverse effects can be increased when Celecoxib is combined with Mometasone.	Approved, Investigational
Ceritinib	Mometasone may increase the hyperglycemic activities of Ceritinib.	Approved
Chloroquine	The risk or severity of adverse effects can be increased when Chloroquine is combined with Mometasone.	Approved, Vet Approved
Chlorothiazide	Mometasone may increase the hypokalemic activities of Chlorothiazide.	Approved, Vet Approved
Chlorotrianisene	The serum concentration of Mometasone can be increased when it is combined with Chlorotrianisene.	Withdrawn
Chlorthalidone	Mometasone may increase the hypokalemic activities of Chlorthalidone.	Approved
Cholestyramine	Cholestyramine can cause a decrease in the absorption of Mometasone resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Choline magnesium trisalicylate	The risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Mometasone.	Approved
Cinoxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Cinoxacin.	Approved, Withdrawn
Ciprofloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Ciprofloxacin.	Approved, Investigational
Clarithromycin	The serum concentration of Mometasone can be increased when it is combined with Clarithromycin.	Approved
Clonixin	The risk or severity of adverse effects can be increased when Clonixin is combined with Mometasone.	Approved
Cobicistat	The serum concentration of Mometasone can be increased when it is combined with Cobicistat.	Approved
Colesevelam	Colesevelam can cause a decrease in the absorption of Mometasone resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Colestipol	Colestipol can cause a decrease in the absorption of Mometasone resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Conjugated estrogens	The serum concentration of Mometasone can be increased when it is combined with Conjugated Equine Estrogens.	Approved
Corticorelin ovine triflutate	The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Mometasone.	Approved
Curcumin	The risk or severity of adverse effects can be increased when Curcumin is combined with Mometasone.	Investigational
Darunavir	The serum concentration of Mometasone can be increased when it is combined with Darunavir.	Approved
Decamethonium	The risk or severity of adverse effects can be increased when Mometasone is combined with Decamethonium.	Approved
Deferasirox	The risk or severity of adverse effects can be increased when Mometasone is combined with Deferasirox.	Approved, Investigational
Demecarium	The risk or severity of adverse effects can be increased when Mometasone is combined with Demecarium.	Approved
Diclofenac	The risk or severity of adverse effects can be increased when Diclofenac is combined with Mometasone.	Approved, Vet Approved
Dienestrol	The serum concentration of Mometasone can be increased when it is combined with Dienestrol.	Approved
Diethylstilbestrol	The serum concentration of Mometasone can be increased when it is combined with Diethylstilbestrol.	Approved
Diflunisal	The risk or severity of adverse effects can be increased when Diflunisal is combined with Mometasone.	Approved
Dihydrotestosterone	Mometasone may increase the fluid retaining activities of Dihydrotestosterone.	Illicit
Donepezil	The risk or severity of adverse effects can be increased when Mometasone is combined with Donepezil.	Approved
Droxicam	The risk or severity of adverse effects can be increased when Droxicam is combined with Mometasone.	Approved
Duvelisib	The risk or severity of adverse effects can be increased when Duvelisib is combined with Mometasone.	Investigational
E-6201	The risk or severity of adverse effects can be increased when E6201 is combined with Mometasone.	Investigational
Ebselen	The risk or severity of adverse effects can be increased when Ebselen is combined with Mometasone.	Investigational
Echothiophate	The risk or severity of adverse effects can be increased when Mometasone is combined with Echothiophate.	Approved
Edrophonium	The risk or severity of adverse effects can be increased when Mometasone is combined with Edrophonium.	Approved
Enoxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Enoxacin.	Approved
Enzalutamide	The serum concentration of Mometasone can be decreased when it is combined with Enzalutamide.	Approved
Epirizole	The risk or severity of adverse effects can be increased when Epirizole is combined with Mometasone.	Approved
Equol	The serum concentration of Mometasone can be increased when it is combined with S Equol.	Investigational
Estradiol	The serum concentration of Mometasone can be increased when it is combined with Estradiol.	Approved, Investigational, Vet Approved
Estriol	The serum concentration of Mometasone can be increased when it is combined with Estriol.	Approved, Vet Approved
Estrone	The serum concentration of Mometasone can be increased when it is combined with Estrone.	Approved
Etacrynic acid	Mometasone may increase the hypokalemic activities of Etacrynic acid.	Approved
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Mometasone.	Approved, Investigational
Ethinyl Estradiol	The serum concentration of Mometasone can be increased when it is combined with Ethinyl Estradiol.	Approved
Etodolac	The risk or severity of adverse effects can be increased when Etodolac is combined with Mometasone.	Approved, Investigational, Vet Approved
Etofenamate	The risk or severity of adverse effects can be increased when Etofenamate is combined with Mometasone.	Approved
Etoricoxib	The risk or severity of adverse effects can be increased when Etoricoxib is combined with Mometasone.	Approved, Investigational
Fenbufen	The risk or severity of adverse effects can be increased when Fenbufen is combined with Mometasone.	Approved
Fenoprofen	The risk or severity of adverse effects can be increased when Fenoprofen is combined with Mometasone.	Approved
Fleroxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Fleroxacin.	Approved
Floctafenine	The risk or severity of adverse effects can be increased when Floctafenine is combined with Mometasone.	Approved, Withdrawn
Flumequine	The risk or severity of adverse effects can be increased when Mometasone is combined with Flumequine.	Withdrawn
Fluoxymesterone	Mometasone may increase the fluid retaining activities of Fluoxymesterone.	Approved, Illicit
Flurbiprofen	The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Mometasone.	Approved, Investigational
Fosaprepitant	The serum concentration of Mometasone can be increased when it is combined with Fosaprepitant.	Approved
Fosphenytoin	The serum concentration of Mometasone can be decreased when it is combined with Fosphenytoin.	Approved
Furosemide	Mometasone may increase the hypokalemic activities of Furosemide.	Approved, Vet Approved
G17DT	The risk or severity of adverse effects can be increased when Mometasone is combined with G17DT.	Investigational
Galantamine	The risk or severity of adverse effects can be increased when Mometasone is combined with Galantamine.	Approved
Gallamine Triethiodide	The risk or severity of adverse effects can be increased when Mometasone is combined with Gallamine Triethiodide.	Approved
Gatifloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Gatifloxacin.	Approved, Investigational
Gemifloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Gemifloxacin.	Approved, Investigational
Genistein	The serum concentration of Mometasone can be increased when it is combined with Genistein.	Investigational
Ginkgo biloba	The risk or severity of adverse effects can be increased when Mometasone is combined with Ginkgo biloba.	Approved, Nutraceutical
Glycerol Phenylbutyrate	The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Mometasone.	Approved
Grepafloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Grepafloxacin.	Withdrawn
Hexestrol	The serum concentration of Mometasone can be increased when it is combined with Hexestrol.	Withdrawn
Higenamine	The risk or severity of adverse effects can be increased when Higenamine is combined with Mometasone.	Investigational
Huperzine A	The risk or severity of adverse effects can be increased when Mometasone is combined with Huperzine A.	Investigational
Hyaluronidase	The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mometasone.	Approved, Investigational
Hydrochlorothiazide	Mometasone may increase the hypokalemic activities of Hydrochlorothiazide.	Approved, Vet Approved
Hydroflumethiazide	Mometasone may increase the hypokalemic activities of Hydroflumethiazide.	Approved
Ibuprofen	The risk or severity of adverse effects can be increased when Ibuprofen is combined with Mometasone.	Approved
Ibuproxam	The risk or severity of adverse effects can be increased when Ibuproxam is combined with Mometasone.	Withdrawn
Icatibant	The risk or severity of adverse effects can be increased when Icatibant is combined with Mometasone.	Approved
Idelalisib	The serum concentration of Mometasone can be increased when it is combined with Idelalisib.	Approved
Indacaterol	Indacaterol may increase the hypokalemic activities of Mometasone.	Approved
Indapamide	Mometasone may increase the hypokalemic activities of Indapamide.	Approved
Indinavir	The serum concentration of Mometasone can be increased when it is combined with Indinavir.	Approved
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Mometasone.	Approved, Investigational
Indoprofen	The risk or severity of adverse effects can be increased when Indoprofen is combined with Mometasone.	Withdrawn
INGN 201	The risk or severity of adverse effects can be increased when Mometasone is combined with INGN 201.	Investigational
INGN 225	The risk or severity of adverse effects can be increased when Mometasone is combined with INGN 225.	Investigational
Isoflurophate	The risk or severity of adverse effects can be increased when Mometasone is combined with Isoflurophate.	Approved, Withdrawn
Isoniazid	The serum concentration of Isoniazid can be decreased when it is combined with Mometasone.	Approved
Isoxicam	The risk or severity of adverse effects can be increased when Isoxicam is combined with Mometasone.	Withdrawn
Itraconazole	The serum concentration of Mometasone can be increased when it is combined with Itraconazole.	Approved, Investigational
Kebuzone	The risk or severity of adverse effects can be increased when Kebuzone is combined with Mometasone.	Experimental
Ketoconazole	The serum concentration of Mometasone can be increased when it is combined with Ketoconazole.	Approved, Investigational
Ketoprofen	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Mometasone.	Approved, Vet Approved
Ketorolac	The risk or severity of adverse effects can be increased when Ketorolac is combined with Mometasone.	Approved
Leflunomide	The risk or severity of adverse effects can be increased when Leflunomide is combined with Mometasone.	Approved, Investigational
Levofloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Levofloxacin.	Approved, Investigational
Lisofylline	The risk or severity of adverse effects can be increased when Lisofylline is combined with Mometasone.	Investigational
Lomefloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Lomefloxacin.	Approved
Lopinavir	The serum concentration of Mometasone can be increased when it is combined with Lopinavir.	Approved
Lornoxicam	The risk or severity of adverse effects can be increased when Lornoxicam is combined with Mometasone.	Approved
Loxapine	The risk or severity of adverse effects can be increased when Mometasone is combined with Loxapine.	Approved
Loxoprofen	The risk or severity of adverse effects can be increased when Loxoprofen is combined with Mometasone.	Approved
Lumacaftor	The serum concentration of Mometasone can be decreased when it is combined with Lumacaftor.	Approved
Lumiracoxib	The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Mometasone.	Approved, Investigational
Magaldrate	The bioavailability of Mometasone can be decreased when combined with Magaldrate.	Withdrawn
Magnesium carbonate	The bioavailability of Mometasone can be decreased when combined with Magnesium carbonate.	Approved
Magnesium Hydroxide	The bioavailability of Mometasone can be decreased when combined with Magnesium hydroxide.	Approved
Magnesium oxide	The bioavailability of Mometasone can be decreased when combined with Magnesium oxide.	Approved
Magnesium salicylate	The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Mometasone.	Approved
Magnesium Trisilicate	The bioavailability of Mometasone can be decreased when combined with Magnesium Trisilicate.	Approved
Malathion	The risk or severity of adverse effects can be increased when Mometasone is combined with Malathion.	Approved, Investigational
Masoprocol	The risk or severity of adverse effects can be increased when Masoprocol is combined with Mometasone.	Approved
Meclofenamic acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mometasone.	Approved, Vet Approved
Mefenamic acid	The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Mometasone.	Approved
Mefloquine	The risk or severity of adverse effects can be increased when Mometasone is combined with Mefloquine.	Approved
Meloxicam	The risk or severity of adverse effects can be increased when Meloxicam is combined with Mometasone.	Approved, Vet Approved
Memantine	The risk or severity of adverse effects can be increased when Mometasone is combined with Memantine.	Approved, Investigational
Mesalazine	The risk or severity of adverse effects can be increased when Mesalazine is combined with Mometasone.	Approved
Mestranol	The serum concentration of Mometasone can be increased when it is combined with Mestranol.	Approved
Metamizole	The risk or severity of adverse effects can be increased when Metamizole is combined with Mometasone.	Withdrawn
Methallenestril	The serum concentration of Mometasone can be increased when it is combined with Methallenestril.	Experimental
Methanesulfonyl Fluoride	The risk or severity of adverse effects can be increased when Mometasone is combined with Methanesulfonyl Fluoride.	Investigational
Methyclothiazide	Mometasone may increase the hypokalemic activities of Methyclothiazide.	Approved
Methyltestosterone	Mometasone may increase the fluid retaining activities of Methyltestosterone.	Approved
Metolazone	Mometasone may increase the hypokalemic activities of Metolazone.	Approved
Mifepristone	The therapeutic efficacy of Mometasone can be decreased when used in combination with Mifepristone.	Approved, Investigational
Minaprine	The risk or severity of adverse effects can be increased when Mometasone is combined with Minaprine.	Approved
Mitotane	The serum concentration of Mometasone can be decreased when it is combined with Mitotane.	Approved
Mivacurium	Mivacurium may increase the adverse neuromuscular activities of Mometasone.	Approved
Mizoribine	The risk or severity of adverse effects can be increased when Mizoribine is combined with Mometasone.	Investigational
Moxifloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Moxifloxacin.	Approved, Investigational
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mometasone.	Approved, Investigational
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Mometasone.	Approved
Nabumetone	The risk or severity of adverse effects can be increased when Nabumetone is combined with Mometasone.	Approved
Nafamostat	The risk or severity of adverse effects can be increased when Nafamostat is combined with Mometasone.	Approved, Investigational
Naftifine	The risk or severity of adverse effects can be increased when Naftifine is combined with Mometasone.	Approved
Nalidixic Acid	The risk or severity of adverse effects can be increased when Mometasone is combined with Nalidixic Acid.	Approved
Naproxen	The risk or severity of adverse effects can be increased when Naproxen is combined with Mometasone.	Approved, Vet Approved
Nefazodone	The serum concentration of Mometasone can be increased when it is combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of Mometasone can be increased when it is combined with Nelfinavir.	Approved
Neostigmine	The risk or severity of adverse effects can be increased when Mometasone is combined with Neostigmine.	Approved, Vet Approved
Nepafenac	The risk or severity of adverse effects can be increased when Nepafenac is combined with Mometasone.	Approved
Nevirapine	The serum concentration of Mometasone can be decreased when it is combined with Nevirapine.	Approved
Nicorandil	The risk or severity of adverse effects can be increased when Mometasone is combined with Nicorandil.	Approved
Niflumic Acid	The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Mometasone.	Approved
Nimesulide	The risk or severity of adverse effects can be increased when Nimesulide is combined with Mometasone.	Approved, Withdrawn
Nitroaspirin	The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Mometasone.	Investigational
Norfloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Norfloxacin.	Approved
Ofloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Ofloxacin.	Approved
Olopatadine	The risk or severity of adverse effects can be increased when Olopatadine is combined with Mometasone.	Approved
Olsalazine	The risk or severity of adverse effects can be increased when Olsalazine is combined with Mometasone.	Approved
Oxandrolone	Mometasone may increase the fluid retaining activities of Oxandrolone.	Approved, Investigational
Oxaprozin	The risk or severity of adverse effects can be increased when Oxaprozin is combined with Mometasone.	Approved
Oxymetholone	Mometasone may increase the fluid retaining activities of Oxymetholone.	Approved, Illicit
Oxyphenbutazone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Mometasone.	Withdrawn
Parecoxib	The risk or severity of adverse effects can be increased when Parecoxib is combined with Mometasone.	Approved
Pazufloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Pazufloxacin.	Investigational
Pefloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Pefloxacin.	Approved
Pentobarbital	The serum concentration of Mometasone can be decreased when it is combined with Pentobarbital.	Approved, Vet Approved
Phenobarbital	The serum concentration of Mometasone can be decreased when it is combined with Phenobarbital.	Approved
Phenylacetic acid	The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Mometasone.	Approved
Phenylbutazone	The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Mometasone.	Approved, Vet Approved
Phenylbutyric acid	The therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Mometasone.	Approved, Investigational
Phenytoin	The serum concentration of Mometasone can be decreased when it is combined with Phenytoin.	Approved, Vet Approved
Physostigmine	The risk or severity of adverse effects can be increased when Mometasone is combined with Physostigmine.	Approved
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mometasone.	Approved, Investigational
Piretanide	Mometasone may increase the hypokalemic activities of Piretanide.	Experimental
Pirfenidone	The risk or severity of adverse effects can be increased when Pirfenidone is combined with Mometasone.	Investigational
Piroxicam	The risk or severity of adverse effects can be increased when Piroxicam is combined with Mometasone.	Approved, Investigational
Polythiazide	Mometasone may increase the hypokalemic activities of Polythiazide.	Approved
Posaconazole	The serum concentration of Mometasone can be increased when it is combined with Posaconazole.	Approved, Investigational, Vet Approved
Primidone	The serum concentration of Mometasone can be decreased when it is combined with Primidone.	Approved, Vet Approved
Promestriene	The serum concentration of Mometasone can be increased when it is combined with Promestriene.	Investigational
Propacetamol	The risk or severity of adverse effects can be increased when Propacetamol is combined with Mometasone.	Approved
Prulifloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Prulifloxacin.	Investigational
PTC299	The risk or severity of adverse effects can be increased when PTC299 is combined with Mometasone.	Investigational
Pyridostigmine	The risk or severity of adverse effects can be increased when Mometasone is combined with Pyridostigmine.	Approved
Quinestrol	The serum concentration of Mometasone can be increased when it is combined with Quinestrol.	Approved
Quinethazone	Mometasone may increase the hypokalemic activities of Quinethazone.	Approved
Rapacuronium	Rapacuronium may increase the adverse neuromuscular activities of Mometasone.	Withdrawn
Resveratrol	The risk or severity of adverse effects can be increased when Resveratrol is combined with Mometasone.	Experimental, Investigational
Rifabutin	The serum concentration of Mometasone can be decreased when it is combined with Rifabutin.	Approved
Rifampicin	The serum concentration of Mometasone can be decreased when it is combined with Rifampicin.	Approved
Rifapentine	The serum concentration of Mometasone can be decreased when it is combined with Rifapentine.	Approved
Rindopepimut	The risk or severity of adverse effects can be increased when Mometasone is combined with CDX-110.	Investigational
Ritonavir	The serum concentration of Mometasone can be increased when it is combined with Ritonavir.	Approved, Investigational
Rivastigmine	The risk or severity of adverse effects can be increased when Mometasone is combined with Rivastigmine.	Approved, Investigational
Rofecoxib	The risk or severity of adverse effects can be increased when Rofecoxib is combined with Mometasone.	Investigational, Withdrawn
Rosoxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Rosoxacin.	Approved
Salicylamide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Mometasone.	Approved
Salicylic acid	The risk or severity of adverse effects can be increased when Salicylic acid is combined with Mometasone.	Approved, Vet Approved
Salsalate	The risk or severity of adverse effects can be increased when Salsalate is combined with Mometasone.	Approved
Saquinavir	The serum concentration of Mometasone can be increased when it is combined with Saquinavir.	Approved, Investigational
Secoisolariciresinol	The serum concentration of Mometasone can be increased when it is combined with Secoisolariciresinol.	Investigational
Seratrodast	The risk or severity of adverse effects can be increased when Seratrodast is combined with Mometasone.	Approved
Sparfloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Sparfloxacin.	Approved
SRP 299	The risk or severity of adverse effects can be increased when Mometasone is combined with SRP 299.	Investigational
SRT501	The risk or severity of adverse effects can be increased when SRT501 is combined with Mometasone.	Investigational
St. John's Wort	The serum concentration of Mometasone can be decreased when it is combined with St. John's Wort.	Nutraceutical
Stanozolol	Mometasone may increase the fluid retaining activities of Stanozolol.	Approved, Vet Approved
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mometasone.	Approved
Sulindac	The risk or severity of adverse effects can be increased when Sulindac is combined with Mometasone.	Approved
Suprofen	The risk or severity of adverse effects can be increased when Suprofen is combined with Mometasone.	Approved, Withdrawn
Synthetic Conjugated Estrogens, A	The serum concentration of Mometasone can be increased when it is combined with Synthetic Conjugated Estrogens, A.	Approved
Synthetic Conjugated Estrogens, B	The serum concentration of Mometasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.	Approved
Tacrine	The risk or severity of adverse effects can be increased when Mometasone is combined with Tacrine.	Withdrawn
Telaprevir	The serum concentration of Telaprevir can be decreased when it is combined with Mometasone.	Withdrawn
Telithromycin	The serum concentration of Mometasone can be increased when it is combined with Telithromycin.	Approved
Temafloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Temafloxacin.	Withdrawn
Tenoxicam	The risk or severity of adverse effects can be increased when Tenoxicam is combined with Mometasone.	Approved
Teriflunomide	The risk or severity of adverse effects can be increased when Teriflunomide is combined with Mometasone.	Approved
Testosterone	Mometasone may increase the fluid retaining activities of Testosterone.	Approved, Investigational
Tiaprofenic acid	The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Mometasone.	Approved
Tibolone	The serum concentration of Mometasone can be increased when it is combined with Tibolone.	Approved
Tinoridine	The risk or severity of adverse effects can be increased when Tinoridine is combined with Mometasone.	Investigational
Tolfenamic Acid	The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Mometasone.	Approved
Tolmetin	The risk or severity of adverse effects can be increased when Tolmetin is combined with Mometasone.	Approved
Torasemide	Mometasone may increase the hypokalemic activities of Torasemide.	Approved
Tranilast	The risk or severity of adverse effects can be increased when Tranilast is combined with Mometasone.	Approved, Investigational
Trichlormethiazide	Mometasone may increase the hypokalemic activities of Trichlormethiazide.	Approved, Vet Approved
Trovafloxacin	The risk or severity of adverse effects can be increased when Mometasone is combined with Trovafloxacin.	Approved, Withdrawn
Tubocurarine	The risk or severity of adverse effects can be increased when Mometasone is combined with Tubocurarine.	Approved
Valdecoxib	The risk or severity of adverse effects can be increased when Valdecoxib is combined with Mometasone.	Investigational, Withdrawn
Voriconazole	The serum concentration of Mometasone can be increased when it is combined with Voriconazole.	Approved, Investigational
Warfarin	Mometasone may increase the anticoagulant activities of Warfarin.	Approved
Zaltoprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Mometasone.	Approved
Zileuton	The risk or severity of adverse effects can be increased when Zileuton is combined with Mometasone.	Approved, Investigational, Withdrawn
Zomepirac	The risk or severity of adverse effects can be increased when Zomepirac is combined with Mometasone.	Withdrawn

Food Interactions

Not Available

References

Synthesis Reference

Pui-Ho Yuen, Charles Eckhart, Teresa Etlinger, Nancy Levine, "Mometasone furoate monohydrate, process for making same and pharmaceutical compositions." U.S. Patent US6127353, issued April, 1988.

US6127353

General References

Not Available

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB14902
KEGG Drug	D08227
KEGG Compound	C07816
PubChem Compound	441335
PubChem Substance	46505288
ChemSpider	390090
ChEBI	6970
ChEMBL	CHEMBL1201404
Therapeutic Targets Database	DAP001042
PharmGKB	PA450541
HET	MOF
Drug Product Database	7504
RxList	http://www.rxlist.com/cgi/generic2/momet1.htm
Drugs.com	http://www.drugs.com/cdi/mometasone-spray.html
PDRhealth	http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/nas1518.shtml
Wikipedia	Mometasone

ATC Codes

R03BA07 — Mometasone

R01AD09 — Mometasone

R03AK09 — Formoterol and mometasone

D07XC03 — Mometasone

D07AC13 — Mometasone

AHFS Codes

52:08.08
84:06.00

PDB Entries

Not Available

FDA label

Download (152 KB)

MSDS

Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Active Not Recruiting	Treatment	Spinal Cord Injuries (SCI)	1
1	Completed	Not Available	Healthy Volunteers	1
1	Completed	Treatment	Allergic Rhinitis (AR)	2
1	Completed	Treatment	Asthma Bronchial	1
1	Completed	Treatment	Healthy Volunteers	2
1	Completed	Treatment	Psoriasis Vulgaris	1
1	Completed	Treatment	Moderate, refractory Atopic dermatitis	1
1, 2	Completed	Not Available	Seasonal Allergic Rhinitis (SAR)	1
2	Completed	Treatment	Acute Rhinosinusitis	1
2	Completed	Treatment	Airway Inflammation / Asthma Bronchial	1
2	Completed	Treatment	Asthma Bronchial	6
2	Completed	Treatment	Chronic Rhinosinusitis	1
2	Completed	Treatment	Plaque Psoriasis	1
2	Completed	Treatment	Polyps, Nasal	1
2	Completed	Treatment	Rhinitis, Allergic, Perennial	1
2	Completed	Treatment	Seasonal Allergic Rhinitis (SAR)	2
2	Enrolling by Invitation	Treatment	Oesophagitis, Eosinophilic	1
2	Enrolling by Invitation	Treatment	Polyps, Nasal	1
2	Recruiting	Treatment	Asthma Bronchial	1
2	Recruiting	Treatment	Sickle Cell Disorders	1
2	Suspended	Treatment	Plaque Psoriasis	1
2	Withdrawn	Treatment	Asthma Bronchial	1
3	Active Not Recruiting	Treatment	Asthma Bronchial	2
3	Completed	Not Available	Perennial Allergic Rhinitis (PAR)	1
3	Completed	Supportive Care	Cancer, Breast / Dermatologic Complications / Radiation Toxicity / Skin Reactions Secondary to Radiation Therapy	1
3	Completed	Treatment	Acute Rhinosinusitis	1
3	Completed	Treatment	Allergies / Conjunctivitis / Rhinitis / Rhinoconjunctivitis	2
3	Completed	Treatment	Asthma Bronchial	5
3	Completed	Treatment	Chronic Obstructive Pulmonary Disease (COPD)	2
3	Completed	Treatment	Otitis Media With Effiusion	1
3	Completed	Treatment	Perennial Allergic Rhinitis (PAR)	5
3	Completed	Treatment	Perennial Allergic Rhinitis (PAR) / Rhinitis, Allergic, Perennial	1
3	Completed	Treatment	Polyps, Nasal	2
3	Completed	Treatment	Rhinitis, Allergic, Perennial	4
3	Completed	Treatment	Seasonal Allergic Rhinitis (SAR)	4
3	Not Yet Recruiting	Treatment	Allergic Rhinitis (AR)	2
3	Recruiting	Treatment	Mild Asthma	1
3	Recruiting	Treatment	Polyps, Nasal	1
3	Recruiting	Treatment	Rhinitis, Allergic, Seasonal	1
3	Unknown Status	Not Available	Itching / Nasal Obstruction / Sneezing	1
3	Unknown Status	Treatment	Mild to Moderate Persistent Allergic Rhinitis	1
3	Withdrawn	Treatment	Obstructive Sleep Apnea (Mild, Moderate, Severe) as Per Polysomnography	1
4	Active Not Recruiting	Treatment	Seasonal Allergic Rhinitis (SAR)	1
4	Completed	Not Available	Rhinitis, Allergic, Perennial and Seasonal	1
4	Completed	Not Available	Moderate, refractory Atopic dermatitis	1
4	Completed	Treatment	Adenoidal Hypertrophy	1
4	Completed	Treatment	Adenoids	1
4	Completed	Treatment	Allergic Rhinitis (AR)	2
4	Completed	Treatment	Asthma Bronchial	3
4	Completed	Treatment	Asthma Bronchial / Rhinitis / Sinusitis	1
4	Completed	Treatment	Obstructive Sleep Apnea (OSA) / Perennial Allergic Rhinitis (PAR) / Sleep Disorder	1
4	Completed	Treatment	Psoriasis	1
4	Recruiting	Health Services Research	Early Radiation Dermatitis	1
4	Recruiting	Treatment	Asthma Bronchial / Sinusitis	1
4	Recruiting	Treatment	Chronic Rhinosinusitis Without Nasal Polyps	1
4	Terminated	Treatment	Adenoidectomy / Adenoids Hypertrophy / Nasal Obstruction	1
4	Terminated	Treatment	Asthma Bronchial	2
4	Terminated	Treatment	Asthma Bronchial / Rhinitis, Allergic, Seasonal	1
4	Terminated	Treatment	Perennial Allergic Rhinitis (PAR)	1
4	Terminated	Treatment	Seasonal Allergic Rhinitis (SAR)	1
4	Unknown Status	Basic Science	Polyps, Nasal	1
4	Unknown Status	Treatment	Asthma Bronchial	1
4	Unknown Status	Treatment	Asthma Bronchial / Polyps, Nasal / Sinusitis	1
4	Unknown Status	Treatment	Phimosis	1
4	Unknown Status	Treatment	Vitiligo	1
4	Withdrawn	Treatment	Enuresis / Obstructive Sleep Apnea (OSA) / Sleep Disordered Breathing (SDB)	1
Not Available	Completed	Not Available	Allergic Rhinitis (AR)	1
Not Available	Completed	Not Available	Asthma Bronchial	1
Not Available	Completed	Not Available	Rhinitis, Allergic, Perennial / Rhinitis, Allergic, Seasonal	1
Not Available	Completed	Not Available	Seasonal Allergic Rhinitis (SAR)	1
Not Available	Not Yet Recruiting	Not Available	Asthma in Children	1
Not Available	Recruiting	Not Available	Asthma Bronchial	1
Not Available	Suspended	Treatment	Asthma Bronchial / Rhinitis	1

Pharmacoeconomics

Manufacturers

Schering corp sub schering plough corp
Altana inc
G and w laboratories inc
Glenmark generics inc usa
Taro pharmaceuticals usa inc
Tolmar inc
Nycomed us inc
Perrigo co
Perrigo new york inc
Schering corp
Schering plough healthcare products inc
Schering-Plough

Packagers

Dosage forms

Form	Route	Strength
Inhalant	Respiratory (inhalation)	110 ug/1
Inhalant	Respiratory (inhalation)	220 ug/1
Aerosol	Respiratory (inhalation)	100 ug/1
Aerosol	Respiratory (inhalation)	200 ug/1
Powder	Respiratory (inhalation)	100 mcg
Powder	Respiratory (inhalation)	200 mcg
Powder	Respiratory (inhalation)	400 mcg
Aerosol	Respiratory (inhalation)
Cream	Topical	0.1 %
Lotion	Topical	0.1 %
Ointment	Topical	0.1 %
Cream	Topical	1 mg/g
Lotion	Topical	1 mg/mL
Ointment	Topical	1 mg/g
Lotion	Topical	1 mg/g
Solution	Topical	1 mg/mL
Spray, metered	Nasal	50 ug/1
Spray, metered	Nasal	50 mcg
Cream	Topical	.1 %
Lotion	Topical	.1 %
Aerosol, metered	Respiratory (inhalation)

Prices

Unit description	Cost	Unit
Asmanex 120 Metered Doses 220 mcg/inh Aerosol 0.24 gm Inhaler	230.27USD	inhaler
Asmanex twisthaler 220 mcg #30	131.47USD	inhaler
Asmanex twisthaler 110 mcg #30	121.76USD	inhaler
Nasonex 50 mcg/act Suspension 50 mcg Nasal Spray	116.82USD	inhaler
Elocon 0.1% Lotion 60ml Bottle	86.71USD	bottle
Elocon 0.1% Cream 45 gm Tube	79.13USD	tube
Elocon 0.1% Ointment 45 gm Tube	76.45USD	tube
Mometasone Furoate 0.1% Solution 60ml Bottle	64.99USD	bottle
Mometasone Furoate 0.1% Cream 45 gm Tube	50.96USD	tube
Elocon 0.1% Lotion 30ml Bottle	49.85USD	bottle
Elocon 0.1% Ointment 15 gm Tube	49.85USD	tube
Elocon 0.1% Cream 15 gm Tube	47.68USD	tube
Mometasone Furoate 0.1% Ointment 45 gm Tube	35.99USD	tube
Mometasone Furoate 0.1% Solution 30ml Bottle	32.99USD	bottle
Mometasone Furoate 0.1% Cream 15 gm Tube	29.99USD	tube
Mometasone Furoate 0.1% Ointment 15 gm Tube	19.19USD	tube
Nasonex 50 mcg nasal spray	6.37USD	g
Elocon 0.1% cream	2.69USD	g
Mometasone furoate 0.1% cream	1.42USD	g
Elocom 0.1 % Cream	0.7USD	g
Elocom 0.1 % Ointment	0.63USD	g
Elocom 0.1 % Lotion	0.47USD	g
Pms-Mometasone 0.1 % Ointment	0.35USD	g
Ratio-Mometasone 0.1 % Ointment	0.35USD	g
Taro-Mometasone 0.1 % Ointment	0.35USD	g
Taro-Mometasone 0.1 % Lotion	0.33USD	g

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US5394868	No	1995-06-25	2012-06-25	US
CA2282360	No	2004-11-09	2018-03-16	Canada
CA2091360	No	1997-04-08	2011-09-06	Canada
US6127353	Yes	1998-04-03	2018-04-03	US
US6240918	Yes	1997-08-20	2017-08-20	US
US8173172	Yes	1998-09-17	2018-09-17	US
US6503537	Yes	1998-09-17	2018-09-17	US
US5829434	Yes	1996-05-03	2016-05-03	US
US6068832	No	1997-08-27	2017-08-27	US
US7067502	No	2000-05-21	2020-05-21	US
US7566705	No	2000-05-21	2020-05-21	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	218-220 °C	Not Available
water solubility	Practically insoluble.	Not Available
logP	2.1	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.00523 mg/mL	ALOGPS
logP	2.81	ALOGPS
logP	3.5	ChemAxon
logS	-4.9	ALOGPS
pKa (Strongest Acidic)	12.48	ChemAxon
pKa (Strongest Basic)	-3.3	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	4	ChemAxon
Hydrogen Donor Count	2	ChemAxon
Polar Surface Area	74.6 Å²	ChemAxon
Rotatable Bond Count	2	ChemAxon
Refractivity	110.29 m³·mol^-1	ChemAxon
Polarizability	43.82 Å³	ChemAxon
Number of Rings	4	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.995
Blood Brain Barrier	+	0.9721
Caco-2 permeable	+	0.7845
P-glycoprotein substrate	Substrate	0.7849
P-glycoprotein inhibitor I	Non-inhibitor	0.7635
P-glycoprotein inhibitor II	Non-inhibitor	0.656
Renal organic cation transporter	Non-inhibitor	0.7753
CYP450 2C9 substrate	Non-substrate	0.852
CYP450 2D6 substrate	Non-substrate	0.9135
CYP450 3A4 substrate	Substrate	0.8028
CYP450 1A2 substrate	Non-inhibitor	0.9383
CYP450 2C9 inhibitor	Non-inhibitor	0.8572
CYP450 2D6 inhibitor	Non-inhibitor	0.8429
CYP450 2C19 inhibitor	Non-inhibitor	0.8966
CYP450 3A4 inhibitor	Non-inhibitor	0.6761
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.8898
Ames test	Non AMES toxic	0.8962
Carcinogenicity	Non-carcinogens	0.9393
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	1.9124 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9254
hERG inhibition (predictor II)	Non-inhibitor	0.6092

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.

Kingdom

Organic compounds

Super Class

Lipids and lipid-like molecules

Class

Steroids and steroid derivatives

Sub Class

Pregnane steroids

Direct Parent

Gluco/mineralocorticoids, progestogins and derivatives

Alternative Parents

20-oxosteroids / 11-beta-hydroxysteroids / 17-hydroxysteroids / Halogenated steroids / 3-oxo delta-1,4-steroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Alpha-chloroketones / Secondary alcohols

Substituents

Progestogin-skeleton / 20-oxosteroid / Hydroxysteroid / Halo-steroid / 9-halo-steroid / Oxosteroid / 11-beta-hydroxysteroid / 11-hydroxysteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid

Molecular Framework

Aliphatic homopolycyclic compounds

External Descriptors

11beta-hydroxy steroid, 17alpha-hydroxy steroid, 20-oxo steroid, 3-oxo-Delta(1),Delta(4)-steroid, chlorinated steroid (CHEBI:6970 )

Targets

Details

1. Glucocorticoid receptor

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: agonist

General Function:: Zinc ion binding
Specific Function:: Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:: NR3C1
Uniprot ID:: P04150
Uniprot Name:: Glucocorticoid receptor
Molecular Weight:: 85658.57 Da

References

Isogai M, Shimizu H, Esumi Y, Terasawa T, Okada T, Sugeno K: Binding affinities of mometasone furoate and related compounds including its metabolites for the glucocorticoid receptor of rat skin tissue. J Steroid Biochem Mol Biol. 1993 Feb;44(2):141-5. [PubMed:8439518 ]
Lumry WR: A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J Allergy Clin Immunol. 1999 Oct;104(4 Pt 1):S150-8. [PubMed:10518812 ]
Smith CL, Kreutner W: In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung. 1998 Sep;48(9):956-60. [PubMed:9793625 ]
Zhang X, Moilanen E, Adcock IM, Lindsay MA, Kankaanranta H: Divergent effect of mometasone on human eosinophil and neutrophil apoptosis. Life Sci. 2002 Aug 16;71(13):1523-34. [PubMed:12127907 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Details

2. Progesterone receptor

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: agonist

General Function:: Zinc ion binding
Specific Function:: The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor isoform B (PRB) is involved activation of c-SRC/MAPK signaling on hormone stimulation.Isoform A: inactive in stimulating c-Src/MAPK signaling on hormone stimulation.Isoform 4: Increases mitochondrial ...
Gene Name:: PGR
Uniprot ID:: P06401
Uniprot Name:: Progesterone receptor
Molecular Weight:: 98979.96 Da

References

Madauss KP, Deng SJ, Austin RJ, Lambert MH, McLay I, Pritchard J, Short SA, Stewart EL, Uings IJ, Williams SP: Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J Med Chem. 2004 Jun 17;47(13):3381-7. [PubMed:15189034 ]

Enzymes

Details

1. Cytochrome P450 2C8

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Steroid hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:: CYP2C8
Uniprot ID:: P10632
Uniprot Name:: Cytochrome P450 2C8
Molecular Weight:: 55824.275 Da

References

Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807 ]
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Drug created on June 13, 2005 07:24 / Updated on August 08, 2017 11:05

Structure for DB00764 (Mometasone)

Targets

References

References

Enzymes

References